These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33353828)

  • 1. Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies.
    Hayashi M; Fujita T; Matsushita H
    Eur J Surg Oncol; 2021 Aug; 47(8):1996-2003. PubMed ID: 33353828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
    BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
    Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
    J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
    Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis.
    Parry K; van Rossum PS; Haj Mohammad N; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2017 Jan; 43(1):226-233. PubMed ID: 27424786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor regression grade combined with post-therapy lymph node status: A novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma.
    Yin H; Yao Q; Xie Y; Niu D; Jiang W; Cao H; Feng X; Li Y; Li Y; Zhang X; Shen L; Chen Y
    Cancer Med; 2023 Oct; 12(19):19633-19643. PubMed ID: 37749981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma.
    Derieux S; Svrcek M; Manela S; Lagorce-Pages C; Berger A; André T; Taieb J; Paye F; Voron T
    Dig Liver Dis; 2020 Jan; 52(1):107-114. PubMed ID: 31427088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
    Grizzi G; Petrelli F; Di Bartolomeo M; Viti M; Texeira Moraes M; Luciani A; Passalacqua R; Ghidini M; Tomasello G; Baiocchi GL; Celotti A
    Gastric Cancer; 2022 Sep; 25(5):982-987. PubMed ID: 35704113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
    Wang T; Li C; Li X; Zhai J; Wang S; Shen L
    Eur J Med Res; 2022 Nov; 27(1):239. PubMed ID: 36352476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey.
    Saliba G; Detlefsen S; Carneiro F; Conner J; Dorer R; Fléjou JF; Hahn H; Kamaradova K; Mastracci L; Meijer SL; Sabo E; Sheahan K; Riddell R; Wang N; Yantiss RK; Lundell L; Low D; Vieth M; Klevebro F
    Hum Pathol; 2021 Feb; 108():60-67. PubMed ID: 33221343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of tumor regression grade (TRG) after oncological gastrectomy for gastric cancer.
    Abboretti F; Mantziari S; Didisheim L; Schäfer M; Teixeira Farinha H
    Langenbecks Arch Surg; 2024 Jun; 409(1):199. PubMed ID: 38935163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single-center experience.
    Lombardi PM; Mazzola M; Achilli P; Aquilano MC; De Martini P; Curaba A; Gualtierotti M; Bertoglio CL; Magistro C; Ferrari G
    J Surg Oncol; 2021 Mar; 123(4):923-931. PubMed ID: 33497471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
    Fareed KR; Ilyas M; Kaye PV; Soomro IN; Lobo DN; Parsons SL; Madhusudan S
    Histopathology; 2009 Oct; 55(4):399-406. PubMed ID: 19817890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating Treatment Response in GEJ Adenocarcinoma: The Role of Pretherapeutic and Posttherapeutic Iodine Mapping.
    Graf M; Gawlitza J; Makowski M; Meurer F; Huber T; Ziegelmayer S
    Invest Radiol; 2024 Aug; 59(8):583-588. PubMed ID: 38265075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nodal downstaging to ypN0 after neoadjuvant chemotherapy positively impacts on survival of cT4N+ GC/GEJ patients.
    Wu L; Xing Z; Huang M; Yu H; Qin Y; Jin Q; Zhou Z; Chen J
    J Surg Oncol; 2022 Dec; 126(8):1403-1412. PubMed ID: 36001384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
    Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
    Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.
    Blank S; Lordick F; Bader F; Burian M; Dobritz M; Grenacher L; Becker K; Weichert W; Langer R; Sisic L; Stange A; Jäger D; Büchler M; Bruckner T; Siewert J; Ott K
    Gastric Cancer; 2015 Apr; 18(2):314-25. PubMed ID: 24722800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.